Ovarian Cancer

The preliminary efficacy, safety, and optimal dose of the MUC16xCD3 bispecific antibody ubamatamab alone or in combination with cemiplimab-rwlc continues to be explored in patients with advanced platinum-resistant ovarian cancer in the phase 2 portion of an ongoing, first-in-human, phase 1/2 study.

The addition of batiraxcept to paclitaxel did not significantly improve progression-free survival compared with paclitaxel alone in a prespecified subset of patients with platinum-resistant ovarian cancer who were not previously exposed to bevacizumab, missing the primary end point of the phase 3 AXLerate-OC trial.

The expert panel reviews the KEYNOTE-775 trial, which focused on lenvatinib and pembrolizumab in advanced endometrial cancer.

A panel of gynecologic oncologists review the PHAEDRA study and discuss the overall treatment landscape for endometrial cancer.

Mary “Nora” Disis, MD, expands on key findings from the phase 1/1b study of PRGN-3005, discusses next steps for the trial, and explains how this research aids efforts to effectively utilize CAR T-cell therapy in ovarian cancer and other solid tumors.

Kathleen N. Moore, MD, MS, discusses the investigation of ubamatamab alone or in combination with cemiplimab in patients with recurrent ovarian cancer.

Whitfield B. Growdon, MD, expands on the FDA’s decision to withdraw the later-line indication of olaparib for patients with BRCA-mutated ovarian cancer.

The phase 1/2 UPLIFT trial evaluating the antibody-drug conjugate upifitamab rilsodotin in patients with platinum-resistant ovarian cancer failed to meet its primary end point of investigator-assessed overall response rate in the NaPi2b-positive population.

Experts on endometrial cancer review the NRG-GY018 and RUBY clinical trials.

The expert panel switches its focus to endometrial cancer and discusses recent data from clinical trials.

Treatment with the combination of ENB-003 and pembrolizumab was well tolerated and produced preliminary signs of clinical activity in patients with platinum-refractory or -resistant, microsatellite stable ovarian cancer, and those with other advanced refractory solid tumors.

Expert gynecologic oncologists react to data from the MIRASOL trial, which studied mirvetuximab in patients with platinum-resistant ovarian cancer.

A panel of experts on ovarian cancer review ongoing trials on maintenance therapies for recurrent ovarian cancer.

Shannon Westin, MD, MPH, FACOG, expands on key clinical trial updates in gynecologic oncology shared at the 2023 ASCO Annual Meeting and highlights what she is looking forward to seeing in the future of care for patients with gynecologic malignancies.

A detailed discussion focused on recent data on PARP inhibitors in the recurrent ovarian cancer setting.

Ovarian cancer experts review clinical trial data on the efficacy of later-line therapies in advanced ovarian cancer.

Michael J. Birrer, MD, PhD, highlights the effect of improved molecular characterization in endometrial cancer, the clinical significance of the KEYNOTE-775 trial, and recent changes in the frontline treatment landscape in advanced endometrial cancer.

Heather R. Williams, MD, discusses findings from the phase 3 PRIMA trial in patients with ovarian cancer.

A comprehensive overview of recent clinical trial data on PARP inhibitors in the first-line maintenance setting in ovarian cancer presented at ASCO 2023.

An expert panel highlights current unmet needs in the maintenance setting for ovarian cancer.

Experts on ovarian cancer discuss germline and somatic testing practices and provide clinical insights on factors that influence treatment decisions.

A panel of expert gynecologic oncologists introduce themselves and review frontline maintenance treatment options in ovarian cancer.

Maurie Markman, MD, discusses changes in cancer management as seen in ovarian cancer.

Mary “Nora” Disis, MD, discusses the results of a phase 1/1b study of PRGN-3005 autologous UltraCAR T cells in patients with advanced stage platinum-resistant ovarian cancer.

A survey conducted by the National Comprehensive Cancer Network Best Practices Committee found that 93% of United States cancer centers polled in the report are experiencing a shortage of carboplatin, and 70% currently have a shortage of cisplatin.